HC Wainwright Forecasts Lineage Cell Therapeutics Q1 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for Lineage Cell Therapeutics in a research report issued on Tuesday, March 11th. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.01) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.06) EPS.

A number of other brokerages have also recently issued reports on LCTX. D. Boral Capital reiterated a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday. B. Riley lowered their price target on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday. Finally, Maxim Group reduced their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $4.20.

Lineage Cell Therapeutics Stock Performance

LCTX stock opened at $0.52 on Thursday. The firm has a market cap of $114.62 million, a P/E ratio of -4.33 and a beta of 1.21. The business’s fifty day moving average price is $0.60. Lineage Cell Therapeutics has a 52 week low of $0.48 and a 52 week high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fort Sheridan Advisors LLC increased its stake in Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after purchasing an additional 23,000 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new stake in Lineage Cell Therapeutics during the 4th quarter valued at $29,000. HighTower Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after purchasing an additional 19,100 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after buying an additional 18,053 shares during the period. Finally, Two Sigma Advisers LP boosted its position in Lineage Cell Therapeutics by 312.2% during the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock worth $44,000 after acquiring an additional 65,864 shares during the period. 62.47% of the stock is owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.